A groundbreaking study links iron regulation with polycythemia vera, leading to promising clinical trials aimed at improving patient treatment options.
A significant advancement in the understanding of polycythemia vera (PV) may offer new hope for patients affected by this challenging blood disorder. The latest research highlights the relationship between iron regulation and the disease, revealing that limiting iron access to bone marrow can decrease excessive red blood cell production.
Conducted by the Walter and Eliza Hall Institute (WEHI) in collaboration with the University of Melbourne, the Peter MacCallum Cancer Centre, and Silence Therapeutics, this study is paving the way for clinical trials of a new treatment protocol. This potential therapy targets hepcidin, a hormone crucial for iron management in the body, with the aim of controlling iron levels in patients with PV.
Currently, around 250 Australians are diagnosed with polycythemia vera annually. This chronic condition, characterized by an overproduction of red blood cells, has no known cure. Left untreated, PV can be life-threatening due to the thickening of the blood, which increases the likelihood of strokes and heart attacks.
The typical approach to managing PV involves venesection, a procedure where up to 500mL of blood is withdrawn multiple times a month to relieve symptoms. The new research published in Blood holds the promise of replacing these often painful and frequent blood draws with a simple injection every few months.
Dr. Cavan Bennett, the study’s lead author, highlighted the significance of their finding that restricting iron access to bone marrow is vital for reducing PV severity. "The hormone hepcidin acts as the master regulator of iron availability," Dr. Bennett explained. "Increasing hepcidin levels restricts iron access to the bone marrow, crucial for preventing excessive blood cell production." This research suggests a double-edged benefit: it could minimize PV severity while also addressing iron deficiency issues prevalent among PV patients, who must often avoid iron supplements due to the risk of compounding their condition.
SLN124, the drug at the center of the clinical trials, will test the effectiveness of hepcidin modulation in PV patients. The trials will be conducted across Australia, Malaysia, and the United States, marking the first effort to control hepcidin expression directly in this patient population.
Professor Sant-Rayn Pasricha, senior author and Head of WEHI's Population Health and Immunity Division, underscores the transformative potential of this treatment strategy: "An injection every few weeks would simplify the long-term management of PV, benefiting patients and the healthcare system alike."
SLN124 operates as a gene silencing therapy, aimed at inhibiting a gene that regulates hepcidin in the liver. By temporarily silencing this gene, researchers hope to enhance hepcidin production, leading to reduced disease impact.
The research has been notably rapid, going from concept to trial in just under four years, an impressive feat in the medical research field. This initiative not only holds the potential to alter patient care protocols for PV but also deepens our understanding of the disease itself.
Additionally, the study revealed a surprising genetic connection between polycythemia vera and hemochromatosis, a condition involving excess iron accumulation. Utilizing extensive databases like the UK Biobank, the research team conducted a genome-wide association study involving 440 PV patients, strengthening the argument for iron’s role in the disease. Professor Melanie Bahlo, who leads this research effort, emphasized the unique insights gained through their research methodologies and data access.
By drawing from genetic data, researchers identified mutations that cause hemochromatosis as significant risk factors for developing PV. Such discoveries could lead to enriched understandings of the biological mechanisms that underlie this rare blood cancer.
Dr. Victoria Jackson, a postdoctoral researcher in the lab, contributed to the genetic analysis through her expertise in genome-wide association studies, which played a central role in uncovering these links between iron metabolism and polycythemia vera.
This research, funded by the National Health and Medical Research Council (NHMRC), holds strong promise for advancing treatment strategies for polycythemia vera. It could reshape the management of this chronic condition and improve the quality of life for thousands of patients.
Materials provided by Walter and Eliza Hall Institute. Note: Content may be edited for style and length.
Discussion
Sign in to join the discussion.